PF 6409577

Drug Profile

PF 6409577

Alternative Names: PF-06409577; PF-6409577

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 28 Jul 2015 Discontinued - Phase-I for Diabetic nephropathies (In volunteers) in Belgium (PO)
  • 27 May 2015 Pfizer resumes enrolment in a phase I trial in Diabetic nephropathies (In volunteers) in Belgium (NCT02286882)
  • 24 Apr 2015 Pfizer suspends phase I trial in Diabetic nephropathies (In volunteers) in Belgium (NCT02286882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top